Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Royal Marsden NHS Foundation Trust |
---|---|
Information provided by: | Royal Marsden NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00299286 |
To provide an in vivo measure of the activity of lapatinib. To assess the antiproliferative effects of laptinib in breast cancer, ie how much lapatinib slows down the growth of cancer cells by measuring K167 (a marker of proliferation) in breast tumours before and after a short treatment with lapatinib.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: lapatinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Ages Eligible for Study: | up to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have a histological or cytologic diagnosis of primary breast cancer with a tumour size adequate for multiple core biopsie Informed signed consent Scheduled for primary surgery Expected to be compliant for duration of study Age<80 ECOG performance status 0-2 (Krnofsky >60%) Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan Eligibility of patients receiving medications known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review by the Trial Co-ordinator The effects if lapatinib on the develpoing foetus are unknown. For this reason, women of childbearing potential must agree to use adequate non-hormonal contraception for the duration of study participation.
Able to swallow and retain oral medication.
Exclusion Criteria:
Patients with prior diagnosis of malignancy except in situ disease or basal cell carcinoma of the skin.
Patients may be receiving any other investigational agents or receiving concurrent anticancer therapy. In addition, all herbal (alternative) medicines are excluded.
Evidence of metastatic disease. Use of hormonal therapy such as oral contraceptives or hormaonal replacement therapy within 4 weeks of study entre.
Regular use of steriod hormones or other agents that could influence study endpoints History of allergic reactions attributed to compounds of similar chemical or bologic composition to GW572016.
Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/ social situations that would limit compliance with study requirements.
Study ID Numbers: | CCR2737 |
Study First Received: | March 3, 2006 |
Last Updated: | October 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00299286 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Skin Diseases Breast Neoplasms Lapatinib Breast Diseases |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |